Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer M Zou, R Toivanen, A Mitrofanova, N Floch, S Hayati, Y Sun, ... Cancer discovery 7 (7), 736-749, 2017 | 341 | 2017 |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS … U Platzbecker, MG Della Porta, V Santini, AM Zeidan, RS Komrokji, ... The Lancet 402 (10399), 373-385, 2023 | 87 | 2023 |
Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 2017; 7: 736–749. doi: 10.1158/2159-8290 M Zou, R Toivanen, A Mitrofanova, N Floch, S Hayati, Y Sun, ... Nat Neurosci 15, 215-223, 2011 | 77 | 2011 |
Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia LW Dillon, S Hayati, GW Roloff, I Tunc, M Pirooznia, A Mitrofanova, ... Haematologica 104 (2), 297, 2019 | 37 | 2019 |
Integrative (epi) genomic analysis to predict response to androgen-deprivation therapy in prostate cancer S Panja, S Hayati, NJ Epsi, JS Parrott, A Mitrofanova EBioMedicine 31, 110-121, 2018 | 19 | 2018 |
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-resistant Prostate Cancer. Cancer Discov. 2017. doi: 10.1158/2159-8290 M Zou, R Toivanen, A Mitrofanova, N Floc’h, S Hayati, Y Sun, ... CD-16-1174, 0 | 4 | |
P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY U Platzbecker, S Hayati, A Ahsan, A Verma, S Aluri, S Rose, A Gandhi, ... HemaSphere 7 (S3), e379048e, 2023 | 3 | 2023 |
Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA … S Hayati, AM Zeidan, G Garcia-Manero, U Platzbecker, A Ahsan, ... Blood 142, 1845, 2023 | 2 | 2023 |
Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A … M Hasan, S Vodala, S Hayati, G Garcia-Manero, AK Gandhi, ... Blood 142, 3214, 2023 | 1 | 2023 |
Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study RS Komrokji, MU Guerrero, G Garcia-Manero, AM Zeidan, U Platzbecker, ... Blood 142, 4591, 2023 | 1 | 2023 |
Predictive biomarkers of response to luspatercept in patients with myelofibrosis-(MF) associated anemia: biomarker analysis from the ACE-536-MF-001 study D Jeyaraju, S Hayati, N Marsousi, AT Gerds, F Passamonti, F Sanabria, ... Blood 142, 6330, 2023 | 1 | 2023 |
Comparison of gene expression profiling platforms: translatability of tumor inflammation gene signatures E Anguiano, K Desai, S Hayati, PM Szabo, S Pant, L Wang, N Zhang Cancer Res. 80, 1997-1997, 2020 | 1 | 2020 |
Luspatercept versus epoetin alfa (EA) for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions (RBCT … U Platzbecker, MG Porta, V Santini, AM Zeidan, P Fenaux, RS Komrokji, ... Oncology Research and Treatment, 2024 | | 2024 |
Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker … D Jeyaraju, S Hayati, J Wang, CN Harrison, JJ Kiladjian, C Hernandez, ... Blood 142, 4526, 2023 | | 2023 |
POSTER: MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase … U Platzbecker, S Hayati, A Ahsan, A Verma, S Aluri, S Rose, A Gandhi, ... Clinical Lymphoma Myeloma and Leukemia 23, S184, 2023 | | 2023 |
MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS … G Garcia-Manero, U Platzbecker, V Santini, AM Zeidan, P Fenaux, ... Clinical Lymphoma Myeloma and Leukemia 23, S355-S356, 2023 | | 2023 |
POSTER: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes … G Garcia-Manero, U Platzbecker, V Santini, AM Zeidan, P Fenaux, ... Clinical Lymphoma Myeloma and Leukemia 23, S184, 2023 | | 2023 |
Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic … G Garcia-Manero, U Platzbecker, V Santini, AM Zeidan, P Fenaux, ... Clinical Lymphoma Myeloma and Leukemia 23, S145, 2023 | | 2023 |
MDS-071 Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase III … U Platzbecker, S Hayati, A Ahsan, A Verma, S Aluri, S Rose, A Gandhi, ... Clinical Lymphoma Myeloma and Leukemia 23, S353-S354, 2023 | | 2023 |
P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY S Aluri, A Ahsan, S Hayati, M Ugidos, P Shah, K Lizotte, S Chakraborty, ... HemaSphere 7 (S3), e8463948, 2023 | | 2023 |